Overview

Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer

Status:
Active, not recruiting

Trial end date:
2020-12-31

Target enrollment:

Participant gender:

Summary

This randomized phase 2 study will seek to determine the effectiveness of chemotherapy (physician's choice of vinorelbine, taxane [paclitaxel, docetaxel or nab paclitaxel] or capecitabine) plus trastuzumab vs chemotherapy (physician's choice) plus trastuzumab plus pertuzumab in women with HER2-overexpressing metastatic breast (MBC) that has been previously treated with ado-trastuzumab emtansine (T-DM1) in the metastatic setting.

Phase:

Phase 2

Details

Lead Sponsor:

US Oncology Research

Collaborator:

Genentech, Inc.

Treatments:

Albumin-Bound Paclitaxel
Capecitabine
Docetaxel
Paclitaxel
Pertuzumab
Trastuzumab
Vinblastine
Vinorelbine